BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34691076)

  • 1. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
    Guo M; Qi F; Rao Q; Sun J; Du X; Qi Z; Yang B; Xia J
    Front Immunol; 2021; 12():754961. PubMed ID: 34691076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
    Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
    Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
    Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies.
    Wirtz TH; Loosen SH; Schulze-Hagen M; Gorgulho J; Kandler J; Joerdens M; Demir M; Mohr R; Bruners P; Kuhl C; Trautwein C; Berres ML; Tacke F; Luedde T; Roderburg C
    Clin Transl Sci; 2021 Sep; 14(5):1853-1863. PubMed ID: 33787014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
    Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
    Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma.
    Wang SY; Su TH; Chen BB; Liu CJ; Liu CH; Yang HC; Tseng TC; Chen PJ; Kao JH
    J Formos Med Assoc; 2022 Aug; 121(8):1579-1587. PubMed ID: 35078686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy.
    Kohles N; Nagel D; Jüngst D; Durner J; Stieber P; Holdenrieder S
    Tumour Biol; 2012 Feb; 33(1):33-40. PubMed ID: 21931992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization.
    Kim SS; Cho HJ; Won JH; Bae JI; Kang DR; Lee JD; Shin SJ; Lee KM; Yoo BM; Kim JK; Lee JH; Ahn SJ; Park JH; Cho SW; Cheong JY
    Cytokine; 2015 Dec; 76(2):449-457. PubMed ID: 26163999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients.
    Tang T; Qiu JL; Li GW; Huang MP; Li Y; Li YJ; Gu SZ
    Clin Radiol; 2018 Mar; 73(3):259-265. PubMed ID: 29032942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival.
    Liu M; Liu J; Wang L; Wu H; Zhou C; Zhu H; Xu N; Xie Y
    PLoS One; 2014; 9(10):e109347. PubMed ID: 25275448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles.
    Ren Z; Yue Y; Zhang Y; Dong J; Liu Y; Yang X; Lin X; Zhao X; Wei Z; Zheng Y; Wang T
    Front Immunol; 2021; 12():624789. PubMed ID: 33717135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
    Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization.
    Ke Q; Xiang F; Xiao C; Huang Q; Liu X; Zeng Y; Wang L; Liu J
    BMC Cancer; 2021 Oct; 21(1):1117. PubMed ID: 34663242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients.
    Shim JH; Park JW; Kim JH; An M; Kong SY; Nam BH; Choi JI; Kim HB; Lee WJ; Kim CM
    Cancer Sci; 2008 Oct; 99(10):2037-44. PubMed ID: 19016764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study.
    Sacco R; Bertini M; Petruzzi P; Bertoni M; Bargellini I; Bresci G; Federici G; Gambardella L; Metrangolo S; Parisi G; Romano A; Scaramuzzino A; Tumino E; Silvestri A; Altomare E; Vignali C; Capria A
    World J Gastroenterol; 2009 Apr; 15(15):1843-8. PubMed ID: 19370781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization.
    Ali HEA; Emam AA; Zeeneldin AA; Srour R; Tabashy R; El-Desouky ED; Abd Elmageed ZY; Abdel-Wahab AA
    Clin Biochem; 2019 Mar; 65():45-52. PubMed ID: 30653948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
    Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
    J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.